Women’s Health Diagnostics Market (Device Type: Biopsy Devices, Imaging & Monitoring Systems, Kits & Reagents, and Consumables & Accessories; Test Type: Breast Cancer Testing, Cervical Cancer Testing, Prenatal Genetic Screening & Carrier Testing, Pregnancy Testing, Fertility & Ovulation Testing, Infectious Disease Testing, and Others; and End User: Hospitals, Diagnostic Laboratories & Imaging Centers, Specialty Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Infections in Pregnant Women Drive Demand for Effective Women’s Health Diagnostics Solutions

High risks associated with the transmission of infectious diseases to pregnant women have raised concerns about effective diagnosis of various infections. As such, infectious disease testing type segment of the women’s health diagnostics market is projected to reach a value of ~US$ 19.2 Bn by the end of 2027. Hence, leading players in the market for women’s health diagnostics are increasing their efficacy in laboratory testing solutions to improve patient outcomes. For instance, leading global medical technology company Siemens Healthineers, offers a range of laboratory testing solutions for women related to TORCH (toxoplasmosis, other (e.g., syphilis, HIV), rubella, cytomegalovirus (CMV), and herpes simplex virus) infections, malnutrition, and bone diseases.

Healthcare companies in the women’s health diagnostics market are tapping into opportunities in diagnostic laboratory testing and infectious disease testing, as both the segments are anticipated to grow rapidly during the forecast period. Growing prevalence of infections causing miscarriage and birth defects in infants are fueling the demand for efficacious treatment options in women’s health diagnostics.

Strategic Mergers Offer New Reproductive Health Solutions for Asian Women

Apart from expanding product portfolios, companies in the market for women’s health diagnostics are strengthening their global presence through inorganic strategies such as mergers and acquisitions. For instance, in August 2019, Nova Satra Dx - a provider of innovative diagnostics for cancer, announced its merger with a Singapore-based molecular diagnostic company INEX Innovations Exchange Pte. Ltd., to offer healthcare solutions tailored for Asian women. As such, Asia Pacific accounts for the third-highest revenue in the women’s health diagnostics market. This market in Asia Pacific is anticipated for exponential growth during the forecast period.

Companies are collaborating to offer enhanced treatment options in Asia Pacific. Efforts are being made to increase the availability of faster and more accurate diagnostic tests to improve quality of life in patients. The concept of precision healthcare is another key driver that is creating incremental opportunities for companies. The women’s health diagnostics market is undergoing change with increased efforts toward providing women’s reproductive health solutions.

New Testing Approaches Create Revenue Opportunities for Companies and Healthcare Providers

Complications associated with cervical cancer has led to the availability of new tests for early detection of the human papillomavirus (HPV). As such, in terms of test type, the cervical cancer testing segment of the women’s health diagnostics market is estimated to reach a value of ~US$ 12.5 Bn by 2027. Hence, companies are introducing new testing options to determine the type of HPV that may lead to cancer.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies in the women’s health diagnostics market are increasing R&D to study the ‘two-for-one’ diagnostic approach that not only detects the type of HPV infection, but also evaluates precancerous makers. Patients are increasingly benefitting from this approach, since it serves as a low-cost alternative to diagnose the riskiest forms of HPV infection. Thus, to cater to the convenience of patients, companies in the market for women’s health diagnostics are collaborating with research labs to improve outcomes that help to avoid unnecessary diagnostic procedures. Moreover, healthcare providers are increasing efficacy in novel in-vitro molecular diagnostics procedures to assess high-risk HPV infections.

Optimization of Dual HIV/Syphilis Testing Serves Patient Requirement for Cost-effective Testing Options

Diagnostic laboratory centers are collaborating with renowned universities to introduce new combined HIV/syphilis testing options. For instance, Junco Labs - a provider of smartphone diagnostics, revealed its collaboration with Columbia University to demonstrate the integration of smartphone-connected blood test for combined HIV/syphilis test.

Thus, the diagnostic laboratories & imaging centers end user segment of the women’s health diagnostics market is expected to reach a value of ~US$ 20.7 Bn by 2022. Hence, stakeholders in diagnostic labs are seeking innovations in dual HIV/syphilis tests.

In the women’s health diagnostics market, efforts are being made to increase the availability of point-of-care (POC) treatments for women. Companies in the women’s health diagnostics market are introducing novel testing options that provide qualitative detection of non-TP (Treponema Pallidum) syphilis. However, there is still a need for effective HIV/syphilis testing options that align with the existing target product profile (TPP). Companies in the market for women’s health diagnostics are offering cost-effective and easy-to-assess tests for combined HIV/syphilis diagnosis.

Analysts’ Viewpoint

Companies in the women’s health diagnostics market are offering increased laboratory testing options to assess biomarkers for allergies, thyroid, and renal diseases in women. Companies should increase focus on expansion of diagnostic services in growing economies of Asia Pacific such as Indonesia and Bangladesh.

However, challenges such as poor supply chain management and stock-outs of POC diagnostic tests in developing economies, such as Ghana, pose as a challenge for manufacturing companies. Hence, companies should adopt inventory management techniques and aid health commissions to increase the human resource capacity for ensuring accessibility and sustainability toward POC testing in resource-limited settings.

Women’s Health Diagnostics Market: Overview

Women’s health diagnostics are used to analyze and detect health issues in women such as breast cancer, cervical cancer, fertility & pregnancy testing, and infectious disease testing

The women’s health diagnostics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the women’s health diagnostics market with respect to segments based on device type, test type, end user, and region

The overview section of the report analyzes the market dynamics and trends, such as drivers, restraints, and opportunities that influence the women’s health diagnostics market. The section also covers market revenue projections, market attractiveness analysis, and key market share analysis in order to provide a thorough analysis of the overall competitive scenario in the women’s health diagnostics market.

Women’s Health Diagnostics Market: Key Drivers

The women’s health diagnostics market is driven by menopause, increase in awareness among people about the availability of treatments for sexually transmitted diseases, surge in women health awareness, favorable incentive and reimbursement policies for UTIs, and increase in diseases in women

According to the Society of Obstetricians & Gynecologists of Canada, around 80% women claim to suffer from, at least, one menopausal symptom including mood swings, irritability, interrupted sleep, hot flushes, and vaginal dryness

However, risk of breast cancer with HRT treatment, increase in demand for alternative therapies, and legal obligations are the major factors anticipated to restrain the global market

Market Segmentation: Women’s Health Diagnostics Market

In terms of device type, the women’s health diagnostics market has been classified into biopsy devices, imaging & monitoring systems, kits & reagents, and consumables & accessories. The kits & reagents segment held a major share of the global market in 2018, as kits & reagents are used in tests such as cancer biopsy, prenatal genetic testing, and infectious disease testing.

Based on test type, the women’s health diagnostics market has been categorized into breast cancer testing, cervical cancer testing, prenatal genetic screening & carrier testing, pregnancy testing, fertility & ovulation testing, infectious disease testing, and others. The infectious disease testing segment dominated the market in 2018, owing to high incidence of infectious diseases in women.

In terms of end user, the women’s health diagnostics market has been divided into hospitals, diagnostic laboratories & imaging centers, specialty clinics, and others. The diagnostic laboratories & imaging centers segment accounted for a significant share of the market in 2018. The segment is expected to retain its leadership position during the forecast period. Growth of the segment can be attributed to increase in the number of diagnostic procedures in diagnostic laboratories & imaging centers.

Each of the segments of the women’s health diagnostics market has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenues (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations. 

Regional Overview: Women’s Health Diagnostics Market

In terms of region, the global women’s health diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the global market in 2018. The market in the region is anticipated to be driven by high rate of adoption of women’s health diagnostics for women’s disease analysis.

The study also offers a list of recommendations, highlights, and useful insights of the market, which would help new companies willing to enter the market, and existing companies to increase market shares and help in the decision-making process 

Major Players in Global Market

The women’s health diagnostics report concludes with the company profiles section that includes key information about the major players in the market

Key players operating in the global women’s health diagnostics market include

• Abbott Laboratories
• Becton
• Dickinson and Company
• bioMérieux SA
• F. Hoffmann-La Roche AG
• GE Healthcare
• Hologic, Inc.
• Koninklijke Philips N.V.
• Quest Diagnostics Inc.
• Cardinal Health
• Siemens AG 

Key Questions Answered in Women’s Health Diagnostics Market Report

• How does the development of women’s health diagnostics provide the scope of growth in the women’s health diagnostics market?
• How alliances and partnerships between players are widening the scope of new preservation techniques for women’s health diagnostics?
• What are the revenue share projections of key segments under various criteria in the women’s health diagnostics market during the forecast period?
• Which segment is likely to generate the highest revenue by the end of the forecast period in 2027?
• How is the evolving healthcare system in developing countries in Asia Pacific making an impact on the overall women’s health diagnostics market?

Women’s Health Diagnostics Market – Segmentation

Device Type

• Biopsy Devices
• Imaging & Monitoring Systems
• Ultrasound Devices
• Mammography Systems
• MRI Systems
• Others
• Kits & Reagents
• Consumables & Accessories

Test Type

• Breast Cancer Testing
• Cervical Cancer Testing
• Prenatal Genetic Screening & Carrier Testing
• Pregnancy Testing
• Fertility & Ovulation Testing
• Infectious Disease Testing
• Others

End User

• Hospitals
• Diagnostic Laboratories & Imaging Centers
• Specialty Clinics
• Others

Region

• North America  
• Europe
• Asia Pacific     
• Latin America   
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. 3. Executive Summary: Global Women’s Health Diagnostics Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Women’s Health Diagnostics Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Global Women’s Health Diagnostics Market Analysis and Forecast, by Device Type 

    5.1. Introduction

    5.2. Key Findings

    5.3. Global Women’s Health Diagnostics Market Value Forecast, by Device Type, 2017–2030

        5.3.1. Biopsy Devices

        5.3.2. Imaging & Monitoring System

            5.3.2.1. Ultrasound Devices

            5.3.2.2. Mammography Systems

            5.3.2.3. MRI Systems

            5.3.2.4. Others

        5.3.3. Kits & Reagents

        5.3.4. Consumables & Accessories

    5.4. Global Women’s Health Diagnostics Market Attractiveness, by Device Type 

6. Global Women’s Health Diagnostics Market Analysis and Forecast, by Test Type

    6.1. Introduction & Definition

    6.2. Key Findings 

    6.3. Global Women’s Health Diagnostics Market Value Forecast, by Test Type, 2017–2030

        6.3.1. Breast Cancer Testing

        6.3.2. Cervical Cancer Testing

        6.3.3. Prenatal Genetic Screening & Carrier Testing

        6.3.4. Pregnancy Testing

        6.3.5. Fertility & Ovulation Testing

        6.3.6. Infectious Disease Testing

        6.3.7. Others

    6.4. Global Women’s Health Diagnostics Market Attractiveness, by Test Type

7. Global Women’s Health Diagnostics Market Analysis and Forecast, by End-user 

    7.1. Introduction

    7.2. Key Findings

    7.3. Global Women’s Health Diagnostics Market Value Forecast, by End-user, 2017–2030

        7.3.1. Hospitals

        7.3.2. Diagnostic Laboratories & Imaging Centers

        7.3.3. Specialty Clinics

        7.3.4. Others 

    7.4. Global Women’s Health Diagnostics Market Attractiveness, by End-user 

8. Global Women’s Health Diagnostics Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Women’s Health Diagnostics Market Value Forecast, by Region, 2017–2030

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Women’s Health Diagnostics Market Attractiveness, by Region

9. North America Women’s Health Diagnostics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Women’s Health Diagnostics Market Value Forecast, by Device Type, 2017–2030

        9.2.1. Biopsy Devices

        9.2.2. Imaging & Monitoring System

            9.2.2.1. Ultrasound Devices

            9.2.2.2. Mammography Systems

            9.2.2.3. MRI Systems

            9.2.2.4. Others

        9.2.3. Kits & Reagents

        9.2.4. Consumables & Accessories

    9.3. North America Women’s Health Diagnostics Market Value Forecast, by Test Type, 2017–2030

        9.3.1. Breast Cancer Testing

        9.3.2. Cervical Cancer Testing

        9.3.3. Prenatal Genetic Screening & Carrier Testing

        9.3.4. Pregnancy Testing

        9.3.5. Fertility & Ovulation Testing

        9.3.6. Infectious Disease Testing

        9.3.7. Others

    9.4. North America Women’s Health Diagnostics Market Value Forecast, by End-user, 2017–2030

        9.4.1. Hospitals

        9.4.2. Diagnostic Laboratories & Imaging Centers

        9.4.3. Specialty Clinics

        9.4.4. Others

    9.5. North America Women’s Health Diagnostics Market Value Forecast, by Country, 2017–2030

        9.5.1. U.S.

        9.5.2. Canada

    9.6. North America Women’s Health Diagnostics Market Attractiveness Analysis 

        9.6.1. By Device Type 

        9.6.2. By Test Type 

        9.6.3. By End-user 

        9.6.4. By Country

10. Europe Women’s Health Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Women’s Health Diagnostics Market Value Forecast, by Device Type, 2017–2030

        10.2.1. Biopsy Devices

        10.2.2. Imaging & Monitoring System

            10.2.2.1. Ultrasound Devices

            10.2.2.2. Mammography Systems

            10.2.2.3. MRI Systems

            10.2.2.4. Others

        10.2.3. Kits & Reagents

        10.2.4. Consumables & Accessories

    10.3. Europe Women’s Health Diagnostics Market Value Forecast, by Test Type, 2017–2030

        10.3.1. Breast Cancer Testing

        10.3.2. Cervical Cancer Testing

        10.3.3. Prenatal Genetic Screening & Carrier Testing

        10.3.4. Pregnancy Testing

        10.3.5. Fertility & Ovulation Testing

        10.3.6. Infectious Disease Testing

        10.3.7. Others

    10.4. Europe Women’s Health Diagnostics Market Value Forecast, by End-user, 2017–2030

        10.4.1. Hospitals

        10.4.2. Diagnostic Laboratories & Imaging Centers

        10.4.3. Specialty Clinics

        10.4.4. Others

    10.5. Europe Women’s Health Diagnostics Market Value Forecast, by Country/Sub-region, 2017–2030

        10.5.1. Germany

        10.5.2. U.K.

        10.5.3. France

        10.5.4. Spain

        10.5.5. Italy

        10.5.6. Rest of Europe

    10.6. Europe Women’s Health Diagnostics Market Attractiveness Analysis 

        10.6.1. By Device Type 

        10.6.2. By Test Type

        10.6.3. By End-user 

        10.6.4. By Country/Sub-region

11. Asia Pacific Women’s Health Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Women’s Health Diagnostics Market Value Forecast, by Device Type, 2017–2030

        11.2.1. Biopsy Devices

        11.2.2. Imaging & Monitoring System

            11.2.2.1. Ultrasound Devices

            11.2.2.2. Mammography Systems

            11.2.2.3. MRI Systems

            11.2.2.4. Others

        11.2.3. Kits & Reagents

        11.2.4. Consumables & Accessories

    11.3. Asia Pacific Women’s Health Diagnostics Market Value Forecast, by Test Type, 2017–2030

        11.3.1. Breast Cancer Testing

        11.3.2. Cervical Cancer Testing

        11.3.3. Prenatal Genetic Screening & Carrier Testing

        11.3.4. Pregnancy Testing

        11.3.5. Fertility & Ovulation Testing

        11.3.6. Infectious Disease Testing

        11.3.7. Others

    11.4. Asia Pacific Women’s Health Diagnostics Market Value Forecast, by End-user, 2017–2030

        11.4.1. Hospitals

        11.4.2. Diagnostic Laboratories & Imaging Centers

        11.4.3. Specialty Clinics

        11.4.4. Others

    11.5. Asia Pacific Women’s Health Diagnostics Market Value Forecast, by Country/Sub-region, 2017–2030

        11.5.1. China

        11.5.2. Japan

        11.5.3. India

        11.5.4. Australia & New Zealand

        11.5.5. Rest of Asia Pacific

    11.6. Asia Pacific Women’s Health Diagnostics Market Attractiveness Analysis 

        11.6.1. By Device Type 

        11.6.2. By Test Type 

        11.6.3. By End-user 

        11.6.4. By Country/Sub-region

12. Latin America Women’s Health Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Women’s Health Diagnostics Market Value Forecast, by Device Type, 2017–2030

        12.2.1. Biopsy Devices

        12.2.2. Imaging & Monitoring System

            12.2.2.1. Ultrasound Devices

            12.2.2.2. Mammography Systems

            12.2.2.3. MRI Systems

            12.2.2.4. Others

        12.2.3. Kits & Reagents

        12.2.4. Consumables & Accessories

    12.3. Latin America Women’s Health Diagnostics Market Value Forecast, by Test Type, 2017–2030

        12.3.1. Breast Cancer Testing

        12.3.2. Cervical Cancer Testing

        12.3.3. Prenatal Genetic Screening & Carrier Testing

        12.3.4. Pregnancy Testing

        12.3.5. Fertility & Ovulation Testing

        12.3.6. Infectious Disease Testing

        12.3.7. Others

    12.4. Latin America Women’s Health Diagnostics Market Value Forecast, by End-user, 2017–2030

        12.4.1. Hospitals

        12.4.2. Diagnostic Laboratories & Imaging Centers

        12.4.3. Specialty Clinics

        12.4.4. Others

    12.5. Latin America Women’s Health Diagnostics Market Attractiveness Analysis 

        12.5.1. By Device Type 

        12.5.2. By Test Type 

        12.5.3. By End-user 

        12.5.4. By Country/Sub-region

13. Middle East & Africa Women’s Health Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Women’s Health Diagnostics Market Value Forecast, by Device Type, 2017–2030

        13.2.1. Biopsy Devices

        13.2.2. Imaging & Monitoring System

            13.2.2.1. Ultrasound Devices

            13.2.2.2. Mammography Systems

            13.2.2.3. MRI Systems

            13.2.2.4. Others

        13.2.3. Kits & Reagents

        13.2.4. Consumables & Accessories

    13.3. Middle East & Africa Women’s Health Diagnostics Market Value Forecast, by Test Type, 2017–2030

        13.3.1. Breast Cancer Testing

        13.3.2. Cervical Cancer Testing

        13.3.3. Prenatal Genetic Screening & Carrier Testing

        13.3.4. Pregnancy Testing

        13.3.5. Fertility & Ovulation Testing

        13.3.6. Infectious Disease Testing

        13.3.7. Others

    13.4. Middle East & Africa Women’s Health Diagnostics Market Value Forecast, by End-user, 2017–2030

        13.4.1. Hospitals

        13.4.2. Diagnostic Laboratories & Imaging Centers

        13.4.3. Specialty Clinics

        13.4.4. Others 

    13.5. Middle East & Africa Women’s Health Diagnostics Market Value Forecast, by Country/Sub-region, 2017–2030

        13.5.1. GCC Countries

        13.5.2. South Africa

        13.5.3. Rest of Middle East & Africa

    13.6. Middle East & Africa Women’s Health Diagnostics Market Attractiveness Analysis 

        13.6.1. By Device Type 

        13.6.2. By Test Type

        13.6.3. By End-user 

        13.6.4. By Country/Sub-region

14. Competition Landscape

    14.1. Market Players - Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis, by Company, 2018

    14.3. Company Profiles

        14.3.1. Abbott Laboratories 

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Financial Overview

            14.3.1.3. Product Portfolio

            14.3.1.4. SWOT Analysis 

            14.3.1.5. Strategic Overview

        14.3.2. Becton, Dickinson and Company

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Financial Overview

            14.3.2.3. Product Portfolio

            14.3.2.4. SWOT Analysis 

            14.3.2.5. Strategic Overview

        14.3.3. bioMérieux SA

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Financial Overview

            14.3.3.3. Product Portfolio

            14.3.3.4. SWOT Analysis 

            14.3.3.5. Strategic Overview

        14.3.4. F. Hoffmann-La Roche AG

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Financial Overview

            14.3.4.3. Product Portfolio

            14.3.4.4. SWOT Analysis 

            14.3.4.5. Strategic Overview

        14.3.5. GE Healthcare

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Financial Overview

            14.3.5.3. Product Portfolio

            14.3.5.4. SWOT Analysis 

            14.3.5.5. Strategic Overview

        14.3.6. Hologic, Inc.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Financial Overview

            14.3.6.3. Product Portfolio

            14.3.6.4. SWOT Analysis 

            14.3.6.5. Strategic Overview

        14.3.7. Koninklijke Philips N.V.

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Financial Overview

            14.3.7.3. Product Portfolio

            14.3.7.4. SWOT Analysis 

            14.3.7.5. Strategic Overview

        14.3.8. Quest Diagnostics, Inc.

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Financial Overview

            14.3.8.3. Product Portfolio

            14.3.8.4. SWOT Analysis 

            14.3.8.5. Strategic Overview

        14.3.9. Cardinal Health

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Financial Overview

            14.3.9.3. Product Portfolio

            14.3.9.4. SWOT Analysis 

            14.3.9.5. Strategic Overview

        14.3.10. Siemens AG

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Financial Overview

            14.3.10.3. Product Portfolio

            14.3.10.4. SWOT Analysis 

            14.3.10.5. Strategic Overview